X
<

Who's Watching Bioverativ Now?

PART:
1 2 3 4
Part 3
Who's Watching Bioverativ Now? PART 3 OF 4

How Are Bioverativ’s Key Drugs Positioned after 2Q17?

Alprolix’s revenue trends

In 2Q17, Bioverativ’s (BIVV) Alprolix generated revenues of ~$89.7 million, which represents ~12% growth on a YoY (year-over-year) basis and ~4% growth on a QoQ (quarter-over-quarter) basis. In the US market, Alprolix generated revenues of ~$72.4 million in 2Q17, compared with $63.0 million in 2Q16. Outside the US, Alprolix generated revenues of ~$17.3 million in 2Q17.

In 1H17, Alprolix reported revenues of ~$175.7 million, compared with $155.3 million in 1H16. Bioverativ is trying to expand into new territories for further sales growth. The growth in unit sales of the drug in US markets primarily contributed to Alprolix’s overall revenue growth.

How Are Bioverativ’s Key Drugs Positioned after 2Q17?

Interested in NVO? Don't miss the next report.

Receive e-mail alerts for new research on NVO

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In the US, Alprolix grew ~8% in unit sales volumes. In 1H17, in Japan and Canada, Alprolix witnessed ~22.3% and 26.4% YoY growth, respectively, in unit sales volumes.

About Alprolix

Alprolix is a recombinant coagulation factor IX FC fusion protein used in adults and children with hemophilia B. The drug aims to treat and control bleeding episodes, perioperative control of bleeding, and routine prophylaxis by reducing the frequency of bleeding episodes.

To know more about Alprolix and Eloctate, please refer to Market Realist’s “Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017.”

Eloctate revenue trends

In 2Q17, Bioverativ’s Eloctate saw revenues of ~$174 million, which represented 40% growth YoY and ~12% growth QoQ. In 1H17, Eloctate reported revenues of ~$330 million, compared with $232 million in 1H16.

In the US, Eloctate reported revenues of ~$150.4 million in 2Q17, compared with $110.2 million in 2Q16. Outside US markets, Eloctate reported revenues of ~$23.8 million in 2Q17, compared with $14.4 million in 2Q16.

In Japan, Eloctate grew 59.5% YoY in unit sales volume in 2Q17. In the US and Canada, Eloctate grew ~36.2% and ~129.1% YoY, respectively, in unit sales volumes.

In the US, Eloctate grew 35.8% YoY in unit sales volume in 1H17. In Japan and Canada, Eloctate witnessed a ~79.5% and ~175.9% YoY growth in unit sales volume, respectively, in 1H17.

About Eloctate

Eloctate is a recombinant antihemophilic factor FC fusion protein used in adults and children with hemophilia A. It’s used to manage bleeding episodes, perioperative bleeding, and routine prophylaxis by diminishing the frequency of bleeding episodes.

Bioverativ’s peers in hemophilia drugs market include Bayer (BAYZF), Shire (SHPG), Novo Nordisk (NVO), Pfizer (PFE), and CSL. Notably, the SPDR S&P MIDCAP 400 ETF (MDY) has ~0.38% of its total portfolio BIVV.

X

Please select a profession that best describes you: